<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39327773</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2163-8306</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>CPT: pharmacometrics &amp; systems pharmacology</Title><ISOAbbreviation>CPT Pharmacometrics Syst Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Immunostimulatory/Immunodynamic model of mRNA-1273 to guide pediatric vaccine dose selection.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/psp4.13237</ELocationID><Abstract><AbstractText>COVID-19 vaccines, including mRNA-1273, have been rapidly developed and deployed. Establishing the optimal dose is crucial for developing a safe and effective vaccine. Modeling and simulation have the potential to play a key role in guiding the selection and development of the vaccine dose. In this context, we have developed an immunostimulatory/immunodynamic (IS/ID) model to quantitatively characterize the neutralizing antibody titers elicited by mRNA-1273 obtained from three clinical studies. The developed model was used to predict the optimal vaccine dose for future pediatric trials. A 25-μg primary vaccine series was predicted to meet non-inferiority criteria in young children (aged 2-5 years) and infants (aged 6-23 months). The geometric mean titers and geometric mean ratios for this dose level predicted using the IS/ID model a priori matched those observed in the pediatric clinical study. These findings demonstrate that IS/ID models represent a novel approach to guide data-driven clinical dose selection of vaccines.</AbstractText><CopyrightInformation>© 2024 The Author(s). CPT: Pharmacometrics &amp; Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ivaturi</LastName><ForeName>Vijay</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-6433-1154</Identifier><AffiliationInfo><Affiliation>Pumas-AI, Inc, Dover, Delaware, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Pharmacometrics, MCOPS, Manipal Academy of Higher Education, Manipal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attarwala</LastName><ForeName>Husain</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Weiping</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Baoyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnyder Ghamloush</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girard</LastName><ForeName>Bethany</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Javid</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minnikanti</LastName><ForeName>Saugandhika</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pumas-AI, Inc, Dover, Delaware, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Honghong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Rituparna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CPT Pharmacometrics Syst Pharmacol</MedlineTA><NlmUniqueID>101580011</NlmUniqueID><ISSNLinking>2163-8306</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39327773</ArticleId><ArticleId IdType="doi">10.1002/psp4.13237</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>The World Health Organization. WHO coronavirus (COVID‐19) dashboard. 2022 [cited 2022 Jun 2]. Available from: https://covid19.who.int/</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Stay up to date with your COVID‐19 vaccines. 2022 [cited 2022 April 22]. Available from: https://www.cdc.gov/coronavirus/2019‐ncov/vaccines/stay‐up‐to‐date.html</Citation></Reference><Reference><Citation>John S, Yuzhakov O, Woods A, et al. Multi‐antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell‐mediated immunity. Vaccine. 2018;36:1689‐1699.</Citation></Reference><Reference><Citation>Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261‐279.</Citation></Reference><Reference><Citation>Rhodes SJ, Guedj J, Fletcher HA, et al. Using vaccine immunostimulation/immunodynamic modelling methods to inform vaccine dose decision‐making. NPJ Vaccines. 2018;3:36.</Citation></Reference><Reference><Citation>Le D, Miller JD, Ganusov VV. Mathematical modeling provides kinetic details of the human immune response to vaccination. Front Cell Infect Microbiol. 2014;4:177.</Citation></Reference><Reference><Citation>Chen X, Hickling TP, Vicini P. A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1 – theoretical model. CPT Pharmacometrics Syst Pharmacol. 2014;3:e133.</Citation></Reference><Reference><Citation>Ali K, Berman G, Zhou H, et al. Evaluation of mRNA‐1273 SARS‐CoV‐2 vaccine in adolescents. N Engl J Med. 2021;385:2241‐2251.</Citation></Reference><Reference><Citation>Creech CB, Anderson E, Berthaud V, et al. Evaluation of mRNA‐1273 Covid‐19 vaccine in children 6 to 11 years of age. N Engl J Med. 2022;386:2011‐2023.</Citation></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA‐1273 SARS‐CoV‐2 vaccine. N Engl J Med. 2021;384:403‐416.</Citation></Reference><Reference><Citation>Anderson EJ, Creech CB, Berthaud V, et al. Evaluation of mRNA‐1273 vaccine in children 6 months to 5 years of age. N Engl J Med. 2022;387:1673‐1687.</Citation></Reference><Reference><Citation>Abbas A, Lichtman A, Pillai S. Cellular and Molecular Immunology. Philadelphia: Elsevier Saunders. 2015.</Citation></Reference><Reference><Citation>Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T‐cell responses in tuberculosis. Mucosal Immunol. 2011;4:288‐293.</Citation></Reference><Reference><Citation>Weisel FJ, Appelt UK, Schneider AM, et al. Unique requirements for reactivation of virus‐specific memory B lymphocytes. J Immunol. 2010;185:4011‐4021.</Citation></Reference><Reference><Citation>Ademokun AA, Dunn‐Walters D. Immune responses: primary and secondary. eLS. 2010. Available from: https://onlinelibrary.wiley.com/doi/10.1002/9780470015902.a0000947.pub2</Citation></Reference><Reference><Citation>Tangye SG, Avery DT, Deenick EK, Hodgkin PD. Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J Immunol. 2003;170:686‐694.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Vaccines and preventable diseases: recommended vaccines by age. 2023 [cited 2023 April 3]. Available from: https://www.cdc.gov/vaccines/vpd/vaccines‐age.html</Citation></Reference><Reference><Citation>Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS‐CoV‐2 – preliminary report. N Engl J Med. 2020;383:1920‐1931.</Citation></Reference><Reference><Citation>Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+T cells: differentiation and functions. Clin Dev Immunol. 2012;2012:925135.</Citation></Reference><Reference><Citation>Naasani I. Establishing the pharmacokinetics of genetic vaccines is essential for maximising their safety and efficacy. Clin Pharmacokinet. 2022;61:921‐927.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>